Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Infectious Disease
•
Non-Tubercular Mycobacteria
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Related Questions
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
What additional treatment strategies would you recommend for a patient with a Mycobacterium chelonae and Mycobacterium abscessus infection following bilateral prophylactic mastectomies and implant insertion, who has undergone multiple surgeries and an extended course of IV antibiotics selected based on sensitivities?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
Do you find HZV titers useful in diagnosing shingles sine herpete?
What is your approach to monitoring of inflammatory markers during treatment of native vertebral osteomyelitis?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Is there a role for routine LP in HIV patients with disseminated histoplasmosis even in the absence of CNS signs/symptoms?
Do you recommend routine neurosyphilis testing in patients being evaluated for dementia?
What agent and for how long would you treat a patient with asymptomatic azole-resistant C auris candiduria who is planning to undergo a urological procedure?
